Education
About Us
Working with TipRanks
Follow Us
Biotricity (BTCY)
:BTCY
Top Page
Biotricity
(OTC:BTCY)
Select Model
Select Model
Rating:45Neutral
Price Target:―
Biotricity's stock score is primarily affected by its strong revenue growth contrasted with significant financial challenges. The company's high debt and negative equity pose risks to long-term sustainability. Technical indicators show mixed signals with a slight bearish tendency, while valuation metrics highlight current unprofitability. These factors combine to result in a moderate stock score, reflecting both potential and caution.
Positive Factors
Revenue Growth
The strong revenue growth indicates Biotricity's expanding market presence and successful product adoption, which is crucial for long-term business sustainability.
Innovative Product Offering
Bioflux's innovative technology positions Biotricity as a leader in remote biometric monitoring, enhancing its competitive edge and market differentiation.
Strategic Partnerships
Strategic partnerships can enhance Biotricity's service offerings and market penetration, supporting long-term growth and stability.
Negative Factors
High Debt Levels
High leverage poses a risk to Biotricity's financial health, potentially limiting its ability to invest in growth and innovation.
Negative Cash Flow
Negative cash flow indicates challenges in sustaining operations without external funding, which could impact long-term viability.
Profitability Challenges
Ongoing operational inefficiencies and high costs relative to revenues threaten Biotricity's ability to achieve sustainable profitability.
Biotricity (BTCY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.01M
Dividend YieldN/A
Average Volume (3M)47.30K
Price to Earnings (P/E)―
Beta (1Y)-0.27
Revenue Growth19.51%
EPS Growth86.16%
CountryUS
Employees55
SectorHealthcare
Sector Strength45
IndustryMedical - Devices
Share Statistics
EPS (TTM)-0.03
Shares Outstanding27,797,710
10 Day Avg. Volume24,958
30 Day Avg. Volume47,301
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)-0.24
Price to Sales (P/S)0.53
P/FCF Ratio-3.07
Enterprise Value/Market Cap3.23
Enterprise Value/Revenue2.78
Enterprise Value/Gross Profit3.49
Enterprise Value/Ebitda-161.20
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Biotricity Business Overview & Revenue Model
Company DescriptionBiotricity Inc. (BTCY) is a medical technology company that specializes in the development and commercialization of remote biometric monitoring solutions. The company focuses on delivering innovative, real-time remote monitoring solutions for chronic conditions and lifestyle improvement. Its core product, Bioflux, is a mobile cardiac telemetry device that provides continuous, real-time monitoring for patients with cardiac conditions, enhancing the capabilities of healthcare providers to diagnose and manage these conditions effectively.
How the Company Makes MoneyBiotricity makes money through the sale and leasing of its medical devices, primarily the Bioflux device, to healthcare providers, including hospitals and clinics. Revenue is generated from both the initial sale/lease of the device and ongoing service fees for data monitoring and analysis. The company may also engage in partnerships with healthcare organizations to expand its reach and enhance service offerings. Additionally, Biotricity may explore revenue opportunities through research and development collaborations in the medical technology sector.
Biotricity Earnings Call Summary
Earnings Call Date:Nov 14, 2025
(Q2-2026)
| % Change Since: |
Next Earnings Date:Feb 17, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant revenue growth, improved gross profit, and positive EBITDA, indicating progress towards profitability. Despite a net loss and increased operating expenses, the strategic advancements and positive financial trends suggest a strong positive outlook.Q2-2026 Updates
Positive Updates
Revenue Growth
For the second quarter of fiscal '26, revenue increased by 19% compared to the corresponding prior year period, reaching $3.9 million.
Improved Gross Profit
Gross profit for the quarter totaled $3.2 million, up 29.4% from the prior year period, with gross profit percentage improving by 660 basis points to 81.9%.
Positive EBITDA
The company achieved a positive EBITDA of $373,000 for the second consecutive quarter, indicating progress towards full profitability.
Advancements in Cardiac Monitoring Technology
Development of the Biocore Pro 2 cardiac monitor and expansion of Biocore Pro sales, including pilot programs with hospital networks and clinics.
Strategic Partnerships and Market Expansion
Expansion into VA and leading home care groups, as well as pulmonary and neurology partnerships.
Negative Updates
Net Loss Attributable to Common Shareholders
Net loss for the fiscal 3-month period was $772,000, though it improved from $1.6 million in the prior year period.
Increase in Operating Expenses
Operating expenses for the second quarter increased by 5.1% to $2.9 million compared to the same period last year.
Company Guidance
During Biotricity's Second Quarter Fiscal 2026 conference call, the company reported significant milestones, including a 19% revenue increase to $3.9 million, driven by strong market adoption of their Technology-as-a-Service model and increased sales of the next-gen Biocore Pro cardiac monitoring device. Gross profit rose by 29.4% to $3.2 million, with a gross profit margin of 81.9%, reflecting efficiencies gained through AI and cloud cost improvements. Operating expenses increased slightly to $2.9 million, while the company achieved a positive EBITDA of $373,000, marking its second consecutive profitable quarter. With a focus on innovation, strategic partnerships, and commercial expansion, Biotricity is poised for sustained growth and profitability, aiming to leverage its economies of scale and invest profits into expanding its market share and commercial team.Biotricity Financial Statement Overview
Summary
Biotricity demonstrates robust revenue growth but struggles with profitability and financial stability. The high debt levels and negative equity raise concerns about long-term sustainability. While the company is expanding its top line, achieving profitability and strengthening the balance sheet are critical for future resilience.Income Statement
Biotricity shows a positive revenue growth trend with a 37.6% increase from 2023 to 2024 (TTM), indicating strong top-line expansion. However, the company faces substantial profitability challenges with persistently negative EBIT and net profit margins, reflecting ongoing operational inefficiencies and high costs relative to revenues.45
Neutral
Balance Sheet
The company's balance sheet reveals considerable financial strain. With a negative stockholders' equity and a high debt-to-equity ratio, Biotricity is highly leveraged, indicating potential solvency issues. The equity ratio is also negative, further highlighting financial instability and risk.30
Negative
Cash Flow
Biotricity's cash flow statement shows negative free cash flow, though there is a slight improvement in operating cash flow from previous periods. The operating cash flow to net income ratio is negative, suggesting cash generation challenges. However, positive financing cash flows indicate reliance on external funding to support operations.40
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 15.08M | 13.79M | 12.06M | 9.64M | 7.65M | 3.38M |
| Gross Profit | 12.04M | 10.56M | 8.36M | 5.44M | 4.57M | 1.27M |
| EBITDA | -260.44K | -3.21M | -8.90M | -16.07M | -18.56M | -12.51M |
| Net Income | -4.53M | -8.42M | -14.09M | -18.66M | -29.13M | -15.49M |
Balance Sheet | ||||||
| Total Assets | 6.32M | 5.64M | 5.94M | 6.51M | 16.68M | 4.44M |
| Cash, Cash Equivalents and Short-Term Investments | 308.46K | 365.14K | 786.06K | 570.46K | 12.07M | 2.20M |
| Total Debt | 13.47M | 26.09M | 23.88M | 19.55M | 15.35M | 4.71M |
| Total Liabilities | 37.98M | 35.66M | 35.92M | 26.36M | 18.82M | 11.27M |
| Stockholders Equity | -33.41M | -30.01M | -29.98M | -19.85M | -2.14M | -6.83M |
Cash Flow | ||||||
| Free Cash Flow | -446.64K | -2.38M | -6.69M | -13.55M | -15.19M | -11.08M |
| Operating Cash Flow | -446.64K | -2.38M | -6.69M | -13.55M | -15.16M | -11.08M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | -29.77K | 0.00 |
| Financing Cash Flow | 517.94K | 1.93M | 6.74M | 2.00M | 25.17M | 12.20M |
Biotricity Technical Analysis
Negative
0.52
Price Trends
0.57
Negative
0.54
Negative
0.51
Negative
Market Momentum
-0.03
Positive
40.53
Neutral
19.15
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BTCY, the sentiment is Negative. The current price of 0.52 is below the 20-day moving average (MA) of 0.54, below the 50-day MA of 0.57, and above the 200-day MA of 0.51, indicating a bearish trend. The MACD of -0.03 indicates Positive momentum. The RSI at 40.53 is Neutral, neither overbought nor oversold. The STOCH value of 19.15 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BTCY.
Biotricity Risk Analysis
Biotricity disclosed 50 risk factors in its most recent earnings report. Biotricity reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Biotricity Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $17.71M | -1.26 | -335.47% | ― | 18.76% | 60.09% | |
45 Neutral | $13.01M | ― | ― | ― | 19.51% | 86.16% | |
43 Neutral | $3.92M | -0.20 | -178.18% | ― | -49.63% | 82.22% | |
41 Neutral | $6.70M | ― | -193.24% | ― | -66.40% | 65.99% | |
37 Underperform | $16.92M | ― | -210.36% | ― | -70.54% | 70.03% | |
35 Underperform | $24.68M | -2.09 | ― | ― | ― | ― |
* Healthcare Sector Average
BTCY
Biotricity
0.46
0.18
64.29%
VVOS
Vivos Therapeutics
2.15
-1.37
-38.92%
ADGM
Adagio Medical Holdings
0.80
-1.78
-68.99%
IINN
Inspira Technologies Oxy BHN
0.96
-0.42
-30.43%
TIVC
Tivic Health Systems
1.72
-2.63
-60.46%
HSCS
Heart Test Laboratories, Inc.
2.53
-0.33
-11.54%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.